Genmab | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
Agios Pharmaceuticals USD 9.47M 1.29M 2024-12
Almirall EUR 231.69M 73.09M 2024-06
Amarin USD 16.28M 26.49M 2024-09
Amgen USD 5.97B 781M 2024-12
argenx SE USD 665.76M 371.88M 2024-12
AstraZeneca USD 12.17B 1.06B 2024-12
Bayer EUR 6.01B 1.13B 2024-12
BioMarin Pharmaceutical USD 611.17M 53.89M 2024-12
Demant DKK 8.58B 4.32B 2024-12
Exelixis USD 546.79M 24.58M 2025-01
Fresenius Medical Care EUR 1.27B 124.43M 2024-12
Galapagos EUR -37430000 97.26M 2024-12
Genmab DKK 6.1B 837M 2024-12
GlaxoSmithKline GBP 5.56B 57M 2024-12
GN Store Nord DKK 2.67B 389M 2024-12
GRIFOLS EUR 766.49M 39.74M 2024-12
Hikma Pharmaceutical USD 756M 82M 2024-06
Insmed USD 78.29M 6.04M 2024-12
Lonza CHF 1.12B 276M 2024-06
Merck EUR 3.1B 45M 2024-12
Novartis USD 10.23B 294M 2024-12
Regeneron Pharmaceuticals USD 3.22B 1.88B 2024-12
Roche Holding CHF 11.69B 48M 2024-12
Sanofi EUR 10.07B 2.1B 2024-09
UCB EUR 970M 788M 2024-06



Genmab Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Apr 2025.